Literature DB >> 991768

[Haemodynamic effect of dobutamine in cardiac failure (author's transl)].

W Delius, A Wirtzfeld, H Sebening, P Mathes.   

Abstract

Dobutamine, a new catecholamine with a positive inotropic action, was given by infusion to 9 patients with cardiac failure in a dosage of 5 and 7.5 mug/kg-min over a period of 15 minutes. An improvement of left ventricular function was proven by an increase of cardiac output by 33%, a reduction of end-diastolic pressure from 21 to 14 mm Hg, an improvement of left ventricular ejection fraction from 29 to 39% and of the mean circumferential fibre contraction velocity from 0.4 to 0.8 circ/s. The systolic aortic pressure increased by a mean of 14% (5 mug/kg-min) and 23% (7.5 mug/kg-min). However, the resistance of the systemic circulation decreased from 1858 to 1439 and 1444 dyn-s-cm-5. Cardiac frequency remained unchanged with a dosage of 5 mug/kg-min and increased by a mere 7 beats/min with a dosage of 7.5 mug/kg-min. There was no increased tendency for arrhythmia. Dobutamine thus appears to act relatively selectively on myocardial beta-1 receptors. Results so far indicate therapeutic success in patients with severe cardiac failure, particularly in the low-output syndrome.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991768     DOI: 10.1055/s-0028-1104332

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Hemodynamic effects of dobutamine in children with cardiovascular failure.

Authors:  D Schranz; H Stopfkuchen; B K Jüngst; R Clemens; P Emmrich
Journal:  Eur J Pediatr       Date:  1982-09       Impact factor: 3.183

2.  [Cardiovascular effects of dobutamine (author's transl)].

Authors:  P Limbourg; H Just; F Kersting; K F Lang
Journal:  Klin Wochenschr       Date:  1978-06-01

3.  Effects of dobutamine on left ventricular performance in newborns as determined by systolic time intervals.

Authors:  H Stopfkuchen; D Schranz; R Huth; B K Jüngst
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.